# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price ...
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also rais...
Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net pro...
All of Summit's Section 16 officers participated in the capital raise. A total of $79 million was raised by insiders, inclu...